Biocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its diabetes drug, Liraglutide, in India. The approval is for a generic version of Victoza. Biocon shares have shown mixed performance recently. The stock closed flat on Monday. The CDSCO clearance came under the expedited 101 route.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets